Evidence map›Paper›PMID 24508386›Full record

Trial reportBone2014

Effects of growth hormone administration for 6 months on bone turnover and bone marrow fat in obese premenopausal women.

Miriam A Bredella, Anu V Gerweck, Lauren A Barber, Anne Breggia, Clifford J Rosen, Martin Torriani, Karen K Miller

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. The effect of growth hormone on bioactive IGF in overweight/obese women.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2018
    Trial
  3. Clonidine increases bone resorption in humans.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
    Trial
  4. Vertebral Strength and Estimated Fracture Risk Across the BMI Spectrum in Women.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016
    Trial
  5. Trial
  6. Review
  7. Bone marrow adiposity in diabetes and clinical interventions.Current opinion in endocrinology, diabetes, and obesity · 2022
    Review
  8. Bone marrow adipose tissue in metabolic health.Trends in endocrinology and metabolism: TEM · 2022
    Review
  9. Cross-sectional associations between adipose tissue depots and areal bone mineral density in the UK Biobank imaging study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Clinical implications of bone marrow adiposity.Journal of internal medicine · 2018
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Miriam A BredellaDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Yawkey 6E, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: mbredella@partners.org.
Anu V GerweckNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Bulfinch 457B, 55 Fruit Street, Boston, MA, USA.
Lauren A BarberDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Yawkey 6E, 55 Fruit Street, Boston, MA 02114, USA.
Anne BreggiaMaine Medical Center Research Institute, Scarborough, ME 04074, USA.
Clifford J RosenMaine Medical Center Research Institute, Scarborough, ME 04074, USA.
Martin TorrianiDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, Yawkey 6E, 55 Fruit Street, Boston, MA 02114, USA.
Karen K MillerNeuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Bulfinch 457B, 55 Fruit Street, Boston, MA, USA.
Harvard University · USMaine Medical Center · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy BalanceR24DK092759 · NIDDK · MAINEHEALTH · PI HOROWITZ, MARK C, MACDOUGALD, ORMOND A · 2011 to 2019
$13.0M
GH, Cardiovascular Risk and Visceral Adiposity in WomenR01HL077674 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · 2007 to 2011
$3.2M
Growth Hormone and Cardiovascular DiseaseK24HL092902 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · 2010 to 2019
$1.6M
EFFECTS OF GROWTH HORMONE ON INTRAMYOCELLULAR LIPIDSK23RR023090 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI BREDELLA, MIRIAM ANTOINETTE · 2007 to 2011
$813k
NCRR NIH HHS K23 RR023090NCRR NIH HHS K23 RR-23090NCRR NIH HHS UL1 RR-025758NCRR NIH HHS UL1 RR025758NHLBI NIH HHS K24 HL092902NHLBI NIH HHS K24 HL092902-03NHLBI NIH HHS R01 HL-077674NHLBI NIH HHS R01 HL077674NIDDK NIH HHS R24 DK092759
6 · The paper itself

Abstract

purposeAbdominal adiposity is associated with low BMD and decreased growth hormone (GH) secretion, an important regulator of bone homeostasis. The purpose of our study was to determine the effects of a short course of GH on markers of bone turnover and bone marrow fat in premenopausal women with abdominal adiposity. MATERIALS AND

methodsIn a 6-month, randomized, double-blind, placebo-controlled trial we studied 79 abdominally obese premenopausal women (21-45 y) who underwent daily sc injections of GH vs. placebo. Main outcome measures were body composition by DXA and CT, bone marrow fat by proton MR spectroscopy, P1NP, CTX, 25(OH)D, hsCRP, undercarboxylated osteocalcin (ucOC), preadipocyte factor 1 (Pref 1), apolipoprotein B (ApoB), and IGF-1.

resultsGH increased IGF-1, P1NP, 25(OH)D, ucOC, bone marrow fat and lean mass, and decreased abdominal fat, hsCRP, and ApoB compared with placebo (p<0.05). There was a trend toward an increase in CTX and Pref-1. Among all participants, a 6-month increase in IGF-1 correlated with 6-month increase in P1NP (p=0.0005), suggesting that subjects with the greatest increases in IGF-1 experienced the greatest increases in bone formation. A six-month decrease in abdominal fat, hsCRP, and ApoB inversely predicted 6-month change in P1NP, and 6-month increase in lean mass and 25(OH)D positively predicted 6-month change in P1NP (p≤0.05), suggesting that subjects with greatest decreases in abdominal fat, inflammation and ApoB, and the greatest increases in lean mass and 25(OH)D experienced the greatest increases in bone formation. A six-month increase in bone marrow fat correlated with 6-month increase in P1NP (trend), suggesting that subjects with the greatest increases in bone formation experienced the greatest increases in bone marrow fat. Forward stepwise regression analysis indicated that increase in lean mass and decrease in abdominal fat were positive predictors of P1NP. When IGF-1 was added to the model, it became the only predictor of P1NP.

conclusionGH replacement in abdominally obese premenopausal women for 6 months increased bone turnover and bone marrow fat. Reductions in abdominal fat, and inflammation, and increases in IGF-1, lean mass and vitamin D were associated with increased bone formation. The increase in bone marrow fat may reflect changes in energy demand from increased bone turnover.

Indexed as

PremenopauseAdiposityAdultApolipoproteins BBiomarkersBody CompositionBone and BonesBone MarrowBone RemodelingFemaleGrowth HormoneHumansInflammationObesityOsteocalcinOsteogenesisApolipoproteins BBiomarkersGrowth HormoneOsteocalcinPeptide FragmentsPlacebosProcollagenprocollagen Type I N-terminal peptideBoneBone marrow fatBone turnoverGrowth hormoneMR spectroscopyObesity

Identifiers

PMID24508386
PMCPMC4014200
OpenAlexW2164811979

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.